This European company focuses on clinical stage development of highly cost effective biological APIs based on their revolutionary patented recombinant technology platform. The company also develops in-vitro diagnostics kits based on a unique pool of recombinantly expressed products
In general terms, the company’s role within R&D initiatives includes the following tasks:
- Manufacturing Proof of Concept of recombinant proteins, chimeric particles, and recombinant antibodies
- Upstream, downstream, analytical, and bioassay development. API manufacturing dossier
- Delivery of tox and clinical material (API)
- Delivery of research-grade recombinant proteins and antibodies
The company has a proven track record on consortia R&D initiatives for biomedical applications and it is looking to study new proposals from Chinese public and private research centres.
The Company’s revolutionary patented technology use a different process to the orthodox fermentation method and is based on insects as micro bio-reactors. As a result development and manufacturing costs are reduced multi-fold, commissioning time lowered, yield is high and linear scalable making it ideal for multiple product facilities.
Benefits of the new technology platform:
- Develop and Manufacture new pharmaceuticals significantly cheaper and quicker
- Can respond to pandemics or Bio threats on local scale
- Can concentrate on niche, orphan and Bio-Similar pharmaceuticals
The company is looking to co-operate with a Chinese company for the development and local manufacture of 2nd generation and Bio-similar pharmaceuticals where the 20-year patent has expired and they have become open to development and manufacture by other companies.
Co-operation Model:
- Joint development and manufacture
- Custom Development & Manufacture of specific pharmaceuticals for Chinese Partner
Expected countries (regions) for cooperation: CHINA .
If you can match this technology offer please contact us quoting: REF:GL1008A-001-TO/Co-operation for the development and local manufacture of 2nd generation and Bio-similar pharmaceuticals
Back |